Circulating Tumor Extracellular Vesicles As Novel Non-invasive Biomarkers to Monitor Metastatic Colorectal Cancer Transcriptomic and Proteomic Evolution
Metastatic colorectal cancer (mCRC) remains a major clinical challenge due to heterogeneous treatment responses and the development of therapeutic resistance. Current tissue-based molecular profiling is limited by invasiveness and the inability to enable longitudinal monitoring. Extracellular vesicles (EVs) represent a promising source of non-invasive biomarkers, carrying stable RNA and proteins reflective of tumor biology. This study aims to identify and validate EV-derived transcriptomic and proteomic biomarkers to monitor disease evolution, predict treatment response, and support personalized management of patients with mCRC.
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients
Extracellular Vesicles in Breast Cancer Patientsin Undergone Neoadjuvant Chemotherapy
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment